Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D-evidence for altered expression in multiple sclerosis

Brain Pathology

Volumn 21, Issue 5, 2011, Pages 544-557

  Zhang, Hua ^a   Hilton, David A ^b   Hanemann, C Oliver ^a   Zajicek, John ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

blood brain barrier; cannabinoid receptors; cerebral endothelial cell; multiple sclerosis; N acyl phosphatidylethanolamine phospholipase D

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; INTERCELLULAR ADHESION MOLECULE 1; N ACYLPHOSPHATIDYLETHANOLAMINE PHOSPHOLIPASE D; PHOSPHOLIPASE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; ASTROCYTE; AUTOPSY; BLOOD BRAIN BARRIER; BRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE ACTIVITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; LEUKOCYTE ADHERENCE; MACROPHAGE; MALE; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ACTINS; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ASTROCYTES; BLOOD VESSELS; BLOOD-BRAIN BARRIER; BRAIN; FEMALE; GENE EXPRESSION REGULATION; HLA-DR ANTIGENS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MACROPHAGES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; PHOSPHOLIPASE D; PHOSPHOPROTEINS; PLAQUE, AMYLOID; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID;

EID: 80052029691     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2011.00477.x     Document Type: Article

References (46)

1. Ashton JC, Appleton I, Darlington CL, Smith PF, (2004) Immunohistochemical localization of cerebrovascular cannabinoid CB1 receptor protein. J Cardiovasc Pharmacol 44: 517-519. (Pubitemid 39441689)
2. Ashton JC, Friberg D, Darlington CL, Smith PF, (2006) Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett 396: 113-116. (Pubitemid 43276423)
3. Baker D, Pryce G, (2008) The endocannabinoid system and multiple sclerosis. Curr Pharm Des 14: 2326-2336.
4. Baker D, Jackson SJ, Pryce G, (2007) Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol 152: 649-654. (Pubitemid 350034985)
5. Benito C, Romero JP, Tolõn RM, Clemente D, Docagne F, Hillard CJ, et al, (2007) Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 27: 2396-2402. (Pubitemid 46340977)
6. Berrendero F, Sánchez A, Cabranes A, Puerta C, Ramos JA, García-Merino A, Fernández-Ruiz J, (2001) Changes in cannabinoid CB (1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41: 195-202. (Pubitemid 32691501)
7. Blázquez C, Casanova ML, Planas A, Gõmez Del Pulgar T, Villanueva C, Fernández-Aceñero MJ, et al, (2003) Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17: 529-531.
8. Cabranes A, Venderova K, de Lago E, Fezza F, Sánchez A, Mestre L, et al, (2005) Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis 20: 207-217. (Pubitemid 41476248)
9. Cabranes A, Pryce G, Baker D, Fernández-Ruiz J, (2006) Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Brain Res 1107: 199-205. (Pubitemid 44205126)
10. Compston A, Coles A, (2002) Multiple sclerosis. Lancet 359: 1221-1231. (Pubitemid 34304266)
11. Cristino L, Starowicz K, De Petrocellis L, Morishita J, Ueda N, Guglielmotti V, Di Marzo V, (2008) Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience 151: 955-968.
12. Curran NM, Griffin BD, O'Toole D, Brady KJ, Fitzgerald SN, Moynagh PN, (2005) The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner. J Biol Chem 280: 35797-35806. (Pubitemid 41633846)
13. Egertová M, Simon GM, Cravatt BF, Elphick MR, (2008) Localization of N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) expression in mouse brain: a new perspective on N-acylethanolamines as neural signaling molecules. J Comp Neurol 506: 604-615.
14. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, et al, (2006) The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49: 67-79. (Pubitemid 43017186)
15. Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, et al, (2004) Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 132: 87-92. (Pubitemid 39531355)
16. Guzman M, (2003) Cannabinoids: potential anticancer agents. Nat Rev Cancer 3: 745-755. (Pubitemid 37328813)
17. Hájos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I, Freund TF, (2000) Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12: 3239-3249.
18. Holley JE, Newcombe J, Whatmore JL, Gutowski NJ, (2010) Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter. Neurosci Lett 470: 65-70.
19. Johnson KP, (2007) Natalizumab (Tysabri) treatment for relapsing multiple sclerosis. Neurologist 13: 182-187. (Pubitemid 47057636)
20. Katona I, Sperlágh B, Maglõczky Z, Sántha E, Köfalvi A, Czirják S, et al, (2000) GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 100: 797-804.
21. Kirk J, Plumb J, Mirakhur M, McQuaid S, (2003) Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 201: 319-327. (Pubitemid 37258943)
22. Leech S, Kirk J, Plumb J, McQuaid S, (2007) Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol 33: 86-98. (Pubitemid 46090313)
23. Loría F, Petrosino S, Hernangõmez M, Mestre L, Spagnolo A, Correa F, et al, (2010) An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol Dis 37: 166-176.
24. Ludwin SK, Henry JM, McFarland HF, (2001) Vascular proliferation and angiogenesis in MS: clinical and pathogenic implications. J Neuropathol Exp Neurol 60: 505.
25. Maccarrone M, Fiori A, Bari M, Granata F, Gasperi V, De Stefano ME, et al, (2006) Regulation by cannabinoid receptors of anandamide transport across the blood-brain barrier and through other endothelial cells. Thromb Haemost 95: 117-127.
26. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN, (2005) Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95: 437-445. (Pubitemid 41457512)
27. Mechoulam R, Shohami E, (2007) Endocannabinoids and traumatic brain injury. Mol Neurobiol 36: 68-74. (Pubitemid 351360359)
28. Mestre L, Correa F, Docagne F, Clemente D, Guaza C, (2006) The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochem Pharmacol 72: 869-880. (Pubitemid 44301054)
29. Mestre L, Docagne F, Correa F, Loría F, Hernangõmez M, Borrell J, Guaza C, (2009) A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol Cell Neurosci 40: 258-266.
30. Molina-Holgado E, Vela JM, Arévalo-Martín A, Almazán G, Molina-Holgado F, Borrell J, Guaza C, (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 22: 9742-9753. (Pubitemid 35332857)
31. Molina-Holgado F, Molina-Holgado E, Guaza C, (1998) The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett 433: 139-142. (Pubitemid 28386745)
32. Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF, (2004) Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 10: 158-164. (Pubitemid 38499908)
33. Ortega-Gutiérrez S, Molina-Holgado E, Arévalo-Martín A, Correa F, Viso A, Lõpez-Rodríguez ML, et al, (2005) Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J 19: 1338-1340. (Pubitemid 41113742)
34. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, Shohami E, (2006) The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 22: 257-264.
35. Pender MP, (2009) Does Epstein-Barr virus infection in the brain drive the development of multiple sclerosis? Brain 132: 3196-3198.
36. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, et al, (2003) Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126: 2191-2202. (Pubitemid 37432364)
37. Rajesh M, Mukhopadhyay P, Bátkai S, Haskõ G, Liaudet L, Huffman JW, et al, (2007) CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 293: H2210-H2218. (Pubitemid 47605864)
38. Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA, et al, (2009) Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1 1501 is regulated by vitamin D. PLoS Genet 5: e1000369.
39. Rodri'guez JJ, Mackie K, Pickel VM, (2001) Ultrastructural localization of the CB1 cannabinoid receptor in μ-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 21: 823-833. (Pubitemid 32163123)
40. Suárez J, Bermúdez-Silva FJ, Mackie K, Ledent C, Zimmer A, Cravatt BF, de Fonseca FR, (2008) Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol 509: 400-421.
41. Trapp BD, Bo L, Mork S, Chang A, (1999) Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 98: 49-56. (Pubitemid 29295407)
42. Voskuhl RR, Peterson RS, Song B, Ao Y, Morales LB, Tiwari-Woodruff S, Sofroniew MV, (2009) Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci 29: 11511-11522.
43. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, et al, (2006) COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6: 12.
44. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362: 1517-1526. (Pubitemid 37410189)
45. Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, et al, (2005) Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 76: 1664-1669. (Pubitemid 41697631)
46. Zhang M, Martin BR, Adler MW, Razdan RJ, Kong W, Ganea D, Tuma RF, (2009) Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmune Pharmacol 4: 249-259.